England and Wales open for potential Leo Pharma recommendation
![Photo: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13914120.ece/ALTERNATES/schema-16_9/doc7kiluwvpppw7vzwo69v.jpg)
The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), is now clarifying an earlier statement, which suggested it did not recommend Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
England and Wales reject Leo Pharma's eczema drug
For subscribers